AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28816693
Drug: Multiple-frequency matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-frequency matching therapy
Trial: 28816693
Drug: Single-frequency matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-frequency matching therapy
Trial: 24257717
Drug: Vortioxetine 15
RxNorm normalized name: vortioxetine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 15 mg/day
Trial: 22100462
Drug: Suspension-exercise-bridge progression
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suspension-exercise-bridge progression
Trial: 16138217
Drug: Purple grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purple grape juice (GJ), 500 ml/day for 14 days
Trial: 16138217
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (RW), 250 ml/day for 14 days
Trial: 12017006
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release formulation of isosorbide-5-mononitrate (40 mg, qd)
Trial: 12017006
Drug: Conventional preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional preparation of isosorbide-5-mononitrate (20 mg, bid)
Trial: 2378185
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms PGE2 gel
Trial: 28080250
Drug: Daclizumab 150
RxNorm normalized name: daclizumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 150 mg subcutaneous
Trial: 28080250
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon beta-1a 30 µg
Trial: 23026182
Drug: Ragweed sublingual
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragweed sublingual allergy immunotherapy tablet (AIT) at doses of 3, 6, 12, 24, 50, or 100 Amb a 1-U, administered once daily for 28 days
Trial: 23026182
Drug: Ragweed sublingual
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ragweed sublingual allergy immunotherapy tablet (AIT)
Trial: 19528135
Drug: Methadone Maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone Maintenance Treatment (MMT) alone
Trial: 19528135
Drug: Injectable opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable opioids (diacetylmorphine or hydromorphone) plus adjunctive MMT if deemed appropriate
Trial: 9722129
Drug: CEE (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE (0.625 mg/day) plus ipriflavone (600 mg/day)
Trial: 9722129
Drug: CEE (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE (0.625 mg/day)
Trial: 9722129
Drug: ipriflavone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipriflavone (600 mg/day)
Trial: 8202971
Drug: Ganglioside GM1
RxNorm normalized name: Ganglioside GM1
DrugBank: Ganglioside GM1 (DB16948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganglioside GM1 100 mg intramuscularly daily for 28 days
Trial: 2562020
Drug: Histological evaluation
RxNorm normalized name: Entamoeba histolytica
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histological evaluation of HA implants
Trial: 433813
Drug: Ethanol (9.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (9.3% w/v aqueous alcohol solution)
Trial: 31144977
Drug: Beta-alanine (BA)
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine (BA) supplementation 30 mg•kg‐1
Trial: 26115073
Drug: Multimodal supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal supervised exercise (group exercise classes twice a week for 12 months and once a week for the subsequent 12 months and home exercises)
Trial: 23348607
Drug: Tofacitinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib at 5 mg twice daily
Trial: 23348607
Drug: Tofacitinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib at 10 mg twice daily
Trial: 17653881
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron alone
Trial: 14998402
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg day(-1) terbinafine
Trial: 14998402
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg day(-1) terbinafine
Trial: 11320011
Drug: Verteporfin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verteporfin (6 mg per square meter of body surface area; n = 81)
Trial: 8446045
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose administration (IV)
Trial: 18194489
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose tolerance test (IVGTT)
Trial: 8446045
Drug: Basal molar
RxNorm normalized name: Polar Freeze
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal molar proinsulin:insulin ratio (P:I)
Trial: 3513687
Drug: Oxymetazoline 0.025%
RxNorm normalized name: OXYMETAZOLINE 0.025% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline 0.025% topical ophthalmic solution
Trial: 30497789
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and low molecular weight dextran (Group A)
Trial: 30497789
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Group B)
Trial: 30497789
Drug: No antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombotic agent (Group C)
Trial: 17481946
Drug: Crataegus extract
RxNorm normalized name: crataegus extract
DrugBank: Hawthorn leaf with flower (DB15839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crataegus extract added to standard HF therapy
Trial: 12150178
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM 12246, 10(10) colony-forming units of each strain, twice daily for 5 days
Trial: 7607715
Drug: Trandolapril 1
RxNorm normalized name: trandolapril 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 1 mg/d
Trial: 7607715
Drug: Trandolapril 4
RxNorm normalized name: trandolapril 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 4 mg/d
Trial: 7607715
Drug: Trandolapril (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (various doses)
Trial: 31084516
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BR) supplementation (340 mg/d)
Trial: 31084516
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) supplementation (<2.5 mg/d)
Trial: 21465243
Drug: Sertraline for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline for an average of 24 days
Trial: 19733706
Drug: Newly initiated
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Newly initiated statin therapy (36 patients)
Trial: 19733706
Drug: Long-term statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-term statin therapy (38 patients)
Trial: 19733706
Drug: Newly initiated
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Newly initiated statin therapy
Trial: 8501178
Drug: HMG-GRF (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMG-GRF (500 micrograms twice daily)
Trial: 3306509
Drug: Doxorubicin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 40 mg/m2 plus melphalan 0.4 mg/kg every four weeks
Trial: 3306509
Drug: Melphalan 1
RxNorm normalized name: diluent for melphalan 10 mL INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melphalan 1 mg/kg every four weeks
Trial: 29539616
Drug: Resveratrol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (2 sprays of 100 µL/spray in each nostril 3 times/day for 1 month)
Trial: 29539616
Drug: Budesonide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (2 sprays of 100 µL/spray in each nostril 3 times/day for 1 month)
Trial: 29539616
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 sprays in each nostril 3 times/day for 1 month)
Trial: 12773137
Drug: PEG-OB (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-OB (80 mg weekly)
Trial: 10574137
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg glycyrrhizin
Trial: 10574137
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg glycyrrhizin
Trial: 10574137
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg glycyrrhizin
Trial: 10574137
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg glycyrrhizin)
Trial: 2063158
Drug: Penicillin-G 5
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin-G 5 million IU
Trial: 6862724
Drug: Thioridazine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (1.0 mg/kg body wt.)
Trial: 6862724
Drug: Thioridazine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (1.5 mg/kg body wt.)
Trial: 6862724
Drug: Thioridazine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (1.0 and 1.5 mg/kg body wt.)
Trial: 31855102
Drug: Endometriosis Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometriosis Health Profile-30 (EHP-30) intervention administered at day 1, month 3 (M3), and month 6 (M6).
Trial: 20026818
Drug: Current intensity-modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current intensity-modulated radiation therapy (IMRT) protocol using the Pinnacle(3) planning system
Trial: 12023504
Drug: Stress reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress reduction interventions (not specified if alone or in combination with pharmacotherapies targeting the HPA axis)
Trial: 12023504
Drug: Drugs affecting
RxNorm normalized name: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs affecting the synthesis and/or secretion of corticosterone
Trial: 12023504
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone (CRH)
Trial: 10463960
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 mg twice daily for two weeks
Trial: 7751683
Drug: OPV containing
RxNorm normalized name: Opvee
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: OPV containing twice the standard potency of Sabin type 1 virus
Trial: 7751683
Drug: Standard formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulations of OPV
Trial: 555487
Drug: Special behavior
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special behavior therapy group
Trial: 555487
Drug: Regular behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular behavior therapy group
Trial: 27533472
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution (500 mL) before abdominal and pelvic CT; n = 2244 patients.
Trial: 20919574
Drug: Reamberin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reamberin (400 ml/day for 10 days)
Trial: 18842392
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of isoflavone
Trial: 18842392
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of casein placebo
Trial: 12050246
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (2 IU/m(2).d)
Trial: 2031520
Drug: Cefoxitin, 2
RxNorm normalized name: CefOXitin, 2 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin, 2 gm intramuscular plus probenecid, 1 gm, followed by doxycycline, 100 mg twice daily for 10 days
Trial: 6759242
Drug: Multiple subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple subcutaneous injections (MSI)
Trial: 31552584
Drug: Hydrocortisone 20
RxNorm normalized name: hydrocortisone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 20 mg per day for 14 days
Trial: 31552584
Drug: Prednisolone once
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone once daily for 14 days
Trial: 25127178
Drug: Trauma-focused Exposure
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused Exposure Therapy (EXP)
Trial: 19243606
Drug: KAb201 via
RxNorm normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAb201 via intravenous route at 50 mCi
Trial: 3362274
Drug: sulindac 200
RxNorm normalized name: sulindac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulindac 200 mg p.o. b.i.d.
Trial: 3362274
Drug: indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indomethacin 25 mg p.o. t.i.d. and 100 mg p.r.
Trial: 31149841
Drug: Cervicothoracic transcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervicothoracic transcutaneous electrical nerve stimulation (CTENS) - 30 min twice daily, 80-Hz frequency, 150-μs pulse duration for 14 days
Trial: 16415316
Drug: BIS 40-50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS 40-50, effect site remifentanil concentration 1 ng ml(‐1)
Trial: 16415316
Drug: BIS 40-50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS 40-50, remifentanil 2 ng ml(‐1)
Trial: 16415316
Drug: BIS 40-50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS 40-50, remifentanil 4 ng ml(‐1)
Trial: 16415316
Drug: BIS 25-35,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS 25-35, remifentanil 2 ng ml(‐1)
Trial: 16415316
Drug: BIS 55-65,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS 55-65, remifentanil 2 ng ml(‐1)
Trial: 15553107
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intravenous orphenadrine citrate
Trial: 11568514
Drug: 20 mg/1.73
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/1.73 m2
Trial: 11568514
Drug: 40 mg/1.73
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/1.73 m2
Trial: 9333107
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg/day for 28 days
Trial: 9333107
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg/day for 28 days
Trial: 8408451
Drug: Dexamethasone (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1.5 mg) pretreatment
Trial: 8408451
Drug: Haloperidol treatment
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol treatment (0.05 mg/kg, i.v.)
Trial: 31651335
Drug: Rapael Smart
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapael Smart Board™ (SB) with 30 min of intervention and 30 min of standard occupational therapy
Trial: 31651335
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CON) with 60 min of conventional occupational therapy
Trial: 29084736
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg/d target dose)
Trial: 21338804
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy diet (OVR) - 1.62 Mcal of NE<sub>L</sub>/kg; 15% crude protein, ad libitum intake
Trial: 21338804
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (CON) - 1.21 Mcal of NE<sub>L</sub>/kg; 14.2% crude protein, 100% NRC requirements
Trial: 21338804
Drug: Restricted intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted intake diet (RES) - 1.62 Mcal of NE<sub>L</sub>/kg; 15% crude protein, 80% of energy requirements
Trial: 17040006
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (4.5, 6.0, or 9.0 g per day)
Trial: 10627097
Drug: Self-reported drinking
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported drinking at treatment admission
Trial: 10627097
Drug: Blood chemistry
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood chemistry values (liver function tests) at treatment admission
Trial: 3592329
Drug: Intramuscular chlorpromazine
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular chlorpromazine (CPZ) 1 mg/kg
Trial: 3592329
Drug: Intramuscular chlorpromazine
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular chlorpromazine (CPZ)
Trial: 25491433
Drug: Mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron 50 mg/day
Trial: 18344738
Drug: PRX-00023 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRX-00023 (80 mg/d)
Trial: 16797903
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training plus vitamin D 400 IU plus 800 mg of calcium per day
Trial: 11094584
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg (T1)
Trial: 11094584
Drug: Tramadol 200
RxNorm normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 200 mg (T2)
Trial: 8930424
Drug: valsartan 20
RxNorm normalized name: valsartan 20 MG in 5 mL Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 20 mg
Trial: 8332965
Drug: Ticlopidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (2 x 250 mg daily) from the second preoperative day until the seventh postoperative day
Trial: 3572208
Drug: Labetalol 200
RxNorm normalized name: HCTZ 25/LABETALOL 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 200 mg
Trial: 3771472
Drug: Labetalol 200
RxNorm normalized name: HCTZ 25/LABETALOL 200MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 200 mg + Isoproterenol
Trial: 3771472
Drug: Labetalol 400
RxNorm normalized name: labetalol 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 400 mg + Isoproterenol
Trial: 3771472
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg + Isoproterenol
Trial: 3771472
Drug: Metoprolol 200
RxNorm normalized name: metoprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 200 mg + Isoproterenol
Trial: 29506504
Drug: Glycopyrronium MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium MDI 3.6 μg
Trial: 29506504
Drug: Ipratropium MDI
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium MDI 34 μg
Trial: 27255474
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (5mg daily for 12 months)
Trial: 25022762
Drug: Whole blood
RxNorm normalized name: Whole blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole blood injection
Trial: 25022762
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection with physical therapy alone
Trial: 22886853
Drug: Low demand,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low demand, high basal infusion (LDHI) strategy
Trial: 22886853
Drug: High demand,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High demand, low basal infusion (HDLI) strategy
Trial: 10802492
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (INO) 20 ppm
Trial: 9252000
Drug: Cervical spine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical spine manipulative physiotherapy treatment
Trial: 1504055
Drug: Recombinant interleukin-2
RxNorm normalized name: Recombinant interleukin-2 human
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant interleukin-2 (rIL-2) administered as a 1- or 2-hour i.v. infusion, with doses of 12 x 10(6) IU/m2, 18 x 10(6) IU/m2, and 24 x 10(6) IU/m2, given every Monday/Wednesday/Friday for 3 weeks